Reviews/Novel Antibiotics/Cefiderocol has excess mortality risk in Acinetobacter baumannii infections
Cefiderocol · NOVEL-AB-CFDC-01 · v2
One large comparison trial [3] found that more patients died while taking cefiderocol than while taking the alternative treatments, and the extra deaths were seen mostly in patients infected with Acinetobacter. That trial, however, was open-label and was explicitly designed only to describe results, not to prove a difference in survival, and the Acinetobacter finding comes from a small slice of its patients. The trial itself did not establish why the extra deaths happened, leaving sicker patients and other differences between the groups as possible explanations. The only other direct comparisons in this corpus [13][14] did not show extra deaths with cefiderocol, though neither was dominated by Acinetobacter patients. Because a real but unexplained numerical signal sits against non-replicating comparisons, the panel treated the claim as unsettled rather than proven.
The pivotal open-label phase 3 trial [3] reports that 34 (34%) of 101 patients on cefiderocol and nine (18%) of 49 on best available therapy died by end of study, with numerically more deaths 'primarily in the patient subset with Acinetobacter spp infections'; Acinetobacter baumannii was the most frequent pathogen (54 of 118 patients, 46%). The trial states the cause of the increased mortality was not established, though it notes only one death (in the comparator arm) was considered related to study drug [3][1]. Against this, a matched ICU cohort [13] found in-ICU mortality comparable between cefiderocol and BAT, though Acinetobacter baumannii was only 14.8% of its pathogens. A pooled metallo-beta-lactamase subset [14] reported day-28 all-cause mortality of 12.5% (3/24) with cefiderocol versus 40-50% for comparators, but this analysis draws partly on the same CREDIBLE-CR population as [3]. The contested point: The corpus divides on whether the higher raw death count in cefiderocol's Acinetobacter subset in [3] represents a drug-attributable risk or an unexplained imbalance in a small, non-randomised-for-mortality subgroup. The counter-evidence [13][14] shows no excess, but neither is Acinetobacter-dominant and [14] is not independent of [3].
All 17 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The sole direct source [3] was an open-label, explicitly descriptive phase 3 trial not powered for mortality; the Acinetobacter finding is an unplanned subgroup of ~54 patients, so a numerical imbalance cannot establish a risk.
Causation is unestablished — the trial does not attribute the deaths to the drug, and an open-label design leaves baseline imbalance and sicker patients as unexcluded confounders.
Where it remains uncertain. The excess rests on one descriptive, non-powered trial subgroup, while the only other comparative data [13][14] show comparable or favourable cefiderocol mortality and are not Acinetobacter-dominant.
Aleatory
The Acinetobacter finding comes from roughly 54 patients in [3] in a trial not powered for mortality, so a numerical death difference could reflect chance rather than a true effect.
Epistemic
Both [3] and [1] state the cause of the increased mortality was not established, leaving the mechanism of any excess unknown.
The load-bearing papers from a corpus of 17, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Quantifies the higher all-cause mortality in the cefiderocol arm versus comparator.
“Numerically more deaths occurred in the cefiderocol group, primarily in the patient subset with Acinetobacter spp infections.”
Panel auditInternal validity: medium · scope of inference: Adults with serious carbapenem-resistant gram-negative infections, with A. baumannii in 54 of 118 carbapenem-resistant microbiological ITT patients.Key limitations: open-label · descriptive, no significance testing · small and heterogeneous subgroups · baseline imbalance possible
Counter-evidence: comparative cohort found no mortality excess versus BAT.
“Clinical cure at 15 and 30-day and the in-ICU mortality was comparable between groups”
Panel auditInternal validity: medium · scope of inference: ICU patients with difficult-to-treat non-fermenting gram-negative bacteria, 81.5% Pseudomonas aeruginosa and 14.8% A. baumannii.Key limitations: mostly Pseudomonas, not A. baumannii · small sample · observational · no mortality statistic reported
Counter-evidence: in the MBL subset cefiderocol mortality was lower than comparators.
“day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators of best-available therapy and high-dose meropenem (40.0% [4/10], 30.0% [3/10], and 50.0% [5/10], respectively)”
Panel auditInternal validity: low · scope of inference: Patients with metallo-β-lactamase-producing gram-negative pathogens across CREDIBLE-CR and APEKS-NP.Key limitations: not A. baumannii-specific · tiny subgroup · pooled across trials · no significance test
3 of 17 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A directly observed but causally unconfirmed single-trial subgroup signal, with non-replicating counter-evidence, supports an Uncertain verdict rather than an established risk.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Powered Acinetobacter-specific randomised comparison. The claim turns on an unplanned subgroup of ~54 patients in a single descriptive trial [3]; no powered randomised test of cefiderocol mortality in Acinetobacter baumannii exists in the corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial of cefiderocol versus comparator restricted to carbapenem-resistant Acinetobacter baumannii infection, pre-specified and powered for all-cause mortality.
Open question: Is cefiderocol associated with higher mortality specifically in Acinetobacter baumannii infections when tested in an adequately powered comparison? Why it is still open: The only direct signal [3] is an unplanned subgroup in a non-powered descriptive open-label trial, and no powered Acinetobacter-specific comparison exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19